FDA approves Novartis' Cosentyx for polymyalgia rheumatica
- Novartis secured FDA approval for Cosentyx 150 mg to treat adults with polymyalgia rheumatica.
- Eligible patients must have an inadequate response to corticosteroids or be unable to tolerate corticosteroid tapering.
- The decision marks Cosentyx’s 11th US indication, making it the first anti-IL-17 biologic approved for the disease.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611162143OMX_____CNEWS_EN_GNW1001303993_en) on November 17, 2026, and is solely responsible for the information contained therein.